Indeed, treatment of T2DM patients with the DPP4i linagliptin was shown tobe associated with a breakdown and reduction of several inflammatory peptides,including incretins, neuropeptide Y, and substance P19. The gene discussed is NPY; the disease is type 2 diabetes mellitus.